ERBB2 and breast cancer: Particularly, 22% of post-hormonal therapy HR+HER2- breast cancers displayed non-overlapping alterations in one or multiple effectors of MAPK signaling or in MYC or other transcription factors; these mutations were mutually exclusive with hotspot mutations in ESR1 [167].